Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $29.1 million.

  • Centessa Pharmaceuticals' Total Current Liabilities rose 1028.55% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.1 million, marking a year-over-year increase of 1028.55%. This contributed to the annual value of $58.0 million for FY2024, which is 4725.91% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Total Current Liabilities of $29.1 million as of Q3 2025, which was up 1028.55% from $29.7 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Total Current Liabilities registered a high of $58.0 million during Q4 2024, and its lowest value of $24.2 million during Q1 2025.
  • In the last 4 years, Centessa Pharmaceuticals' Total Current Liabilities had a median value of $29.7 million in 2025 and averaged $33.1 million.
  • Examining YoY changes over the last 5 years, Centessa Pharmaceuticals' Total Current Liabilities showed a top increase of 4725.91% in 2024 and a maximum decrease of 2445.5% in 2024.
  • Over the past 4 years, Centessa Pharmaceuticals' Total Current Liabilities (Quarter) stood at $38.3 million in 2022, then grew by 2.73% to $39.4 million in 2023, then surged by 47.26% to $58.0 million in 2024, then crashed by 49.79% to $29.1 million in 2025.
  • Its last three reported values are $29.1 million in Q3 2025, $29.7 million for Q2 2025, and $24.2 million during Q1 2025.